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During the last decades, there has been a huge increase in the prevalence of type 2 diabetes mellitus (T2DM), mostly due to the Western lifestyle [1, 2] . T2DM and its vascular complications increase patient morbidity, hospitalisations and healthcare costs [3, 4] . Thus, it is beyond doubt that we need medication which can confer some improvement in the underlying pathophysiological factors leading to T2DM and its complications.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a class of antidiabetic agents, which was introduced in the 21st century. They successfully target not only blood glucose control but also obesity in patients with T2DM [5, 6] . Currently, exenatide, liraglutide, lixisenatide, albiglutide and dulaglutide are already on the market [5, 7] . The newest agent is semaglutide [5] [6] [7] . All GLP-1RAs are used subcutaneously. Albiglutide, dulaglutide and semaglutide show a long action and are administered once weekly [6, [8] [9] [10] [11] . Liraglutide is used once daily. Exenatide exists in two preparations: a quick acting used twice per day, and a long-acting used once per week [6, [8] [9] [10] [11] . An oral form of semaglutide is currently under development [6, [8] [9] [10] [11] . GLP-1 RAs mainly act by activating the GLP-1 receptors in pancreatic beta cells to stimulate glucose-dependent insulin secretion. Additionally, they reduce appetite and delay gastric emptying, eventually leading to reduced food intake [6, [8] [9] [10] . They can be used either as monotherapy or an add-on therapy to other antidiabetic agents, including insulin, in T2DM [11] [12] [13] . GLP-1RAs have very recently been recommended as the second antidiabetic agent after metformin in patients with established atherosclerotic cardiovascular disease and chronic kidney disease [14] . However, they should not be used together with dipeptidyl peptidase-4 inhibitors [10] [11] [12] [13] . As regards type 1 diabetes mellitus, they have been studied but they are not currently approved [9, 11, 13] .
The advantages of GLP-1RAs include: (a) efficacy (reduction of glycated haemoglobin 0.6-1.9% in a period of 24-30 weeks); (b) absence of hypoglycaemias; (c) weight reduction; (d) reduction of appetite; (e) reduction of fatty liver infiltration. These actions are significant and clinically meaningful (see Table 1 ) [5, 10, [11] [12] [13] 15, 16] . Regarding their combination with other antidiabetic agents, there are interesting results from some trials. In a study including patients treated with a GLP-1RA together with a sodium glucose transporter 2 inhibitor (SGLT2), the mean reduction of glucose was 2.2 mmol/L (39.6 mg/dL) (p < 0.0004) after 6 months [17] . This therapeutic combination achieved not only adequate glycaemic control, but also weight loss (2.1 kg; p < 0.00003) and decrease of blood pressure [17] . In addition, 34.3% of patients achieved Hb1Ac levels <7% and weight loss >5%, without hypoglycaemias [17] . These results are also supported by another real-world observational study in with patients receiving a GLP-1RA in combination with metformin and a SGLT-2 inhibitor [18] . The main adverse effects of GLP-1RAs are gastrointestinal: nausea, vomiting, diarrhoea and abdominal complaints (see Table 2 ) [19] . However, these are mostly self-limited over time [19] . Another adverse effect is injection-site reactions [19] . Moreover, there are indications that incretin-based therapies may cause pancreatic diseases. Nevertheless, according to real-world evidence, the risk of pancreatic disease associated with add-on GLP-1RAs to metformin therapy appears to be no higher than that associated with other antidiabetic agents [20] .
Obviously, the need for injection may discourage some patients, but this can easily be overcome with patient education [16, 19] . Moreover, the new pens and (especially) the once-weekly injection of some compounds render them more user friendly [11, 16, 19] . Another consideration is administration and ease of use. For example, albiglutide needs reconstruction before injection, making its use difficult for some patients, including those with visual or dexterity issues [11, 16, 19] .
The most important challenge for GLP-1RAs is, as indeed for all antidiabetic agents, the potential cardioprotective actions [21, 22] . In this context, GLP-1RAs have demonstrated: (a) slight improvements in arterial pressure, lipid parameters and inflammation in humans; (b) improvements in heart failure and myocardial infarction in the experimental setting [21] [22] [23] [24] .
Of particular relevance, GLP-1RAs exhibit important differences in their cardiovascular effects in [25, 26] . By contrast, once-weekly exenatide and lixisenatide have shown a neutral cardiovascular effect: safety but no benefit [27, 28] . These differences need to be appreciated in clinical practice, especially when prescribing antidiabetic treatment to patients with known cardiovascular morbidity [29, 30] . Importantly, in the most recent cardiovascular outcomes trial [31] , once-weekly albiglutide reduced the primary cardiovascular endpoint by 22%, exhibiting superiority compared with placebo (p = 0.0006). This trial further enhances the importance of GLP1RAs, especially in patients with established cardiovascular disease [31, 32] . Furthermore, there is recent evidence that that GLP-1RAs may improve the natural history of diabetic complications. A pharmacovigilance meta-analysis has demonstrated that reduced incidence of retinopathy with GLP-1RAs, as compared to other antidiabetic agents [33] . Importantly, GLP-1RAs appear to exert an additional protective role in the kidneys. According to real-world evidence, their use in patients with low estimated glomerular filtration rate (eGFR) was related to less pronounced reduction in eGFR (−0.80 vs. −1.03 mL/min/1.73 m 2 , p = 0.0005), as compared with other therapies, while HbA1c was significantly reduced as well [34] . Finally, it is now being increasingly appreciated that GLP-1RAs can be excellently be combined with basal insulin [32] . In this more modern combination, GLP-1RAs target post-prandial hyperglycaemia, while basal insulin targets fasting glucose. Nowadays, fixed GLP-1RAs+basal insulin combinations used as a single daily injection in the same pen are available to increase patient compliance [32] .
In conclusion, GLP-1RAs are antidiabetic agents with many advantages [5, 8, 14, 35] . Their beneficial actions are increasingly being appreciated in the treatment of T2DM. 
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